Company
Revolution Medicines
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
7
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
- Phase 111
Recent approvals
Originals and efficacy supplements, newest first.
- Rasonque approved NovelPriority reviewOrphanAug 26, 2026
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07491445 · 900 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2028
Drug: daraxonrasib; gemcitabine and 1 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Los Angeles, California · 106 sites in all
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07621718 · 670 participants (planned) · Start May 22, 2026 · Primary completion Dec 30, 2028
Drug: Zoldonrasib; Placebo and 6 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Tucson, Arizona; New Haven, Connecticut · 25 sites in all
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT06881784 · 590 participants (planned) · Start May 6, 2025 · Primary completion Dec 1, 2027
Drug: daraxonrasib; docetaxel · For: NSCLC (Non-small Cell Lung Cancer); Non-Small Cell Lung Cancer; NSCLC and 2 more
Sites: Birmingham, Alabama; Loma Linda, California; Long Beach, California · 199 sites in all
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)Pivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07252232 · 500 participants (planned) · Start Dec 15, 2025 · Primary completion May 10, 2029
Drug: daraxonrasib · For: Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 86 sites in all
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07777822 · 430 participants (planned) · Start Aug 14, 2026 · Primary completion Oct 2029
Drug: zoldonrasib; Placebo and 2 more · For: NSCLC; Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer NSCLC and 4 more
Sites: Anchorage, Alaska; Fort Lauderdale, Florida; Plantation, Florida · 4 sites in all
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaPivotal-lookingRecruiting
Revolution Medicines, Inc.Industry
NCT07805954 · 400 participants (planned) · Start Aug 28, 2026 · Primary completion Mar 2029
Drug: daraxonrasib; gemcitabine and 2 more · For: Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; Jacksonville, Florida · 6 sites in all
Marketed drugs (1)
Newest FDA action first.
- Rasonque Daraxonrasib · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.